






In 2013, the American College of Cardiology (ACC) and the American Heart Association (AHA) published recommendations for lipid management incorporating a new risk score for assessment of 10-year atherosclerotic cardiovascular disease, abbreviated as ASCVD scores. Statins are recommended for 4 specific groups of adults under the age of 75 years: 1) with vascular disease; 2) an LDL-C ≥ 190mg/dL; 3) with Diabetes Mellitus (DM) (and aged 40 - 75); and 4) with an ASCVD score ≥ 7.5%.  Data on implementation of these recommendations among minority women are scarce. The purpose of this analysis was to examine racial differences in statin eligibility and use.
Methods: 




Of the 2399 women who were included, 234 had a cardiovascular disease diagnosis, 354 had Diabetes Mellitus (DM), 53 had an LDL-C ≥ 190 mg/dL and 174 had an ASCVD risk score ≥ 7.5%.  Rates of statin use among those with elevated risk was low; 49.5% of those with CVD; 61.6% of those with DM, and 13.2% of those with LDL-C ≥ 190 mg/dL. Blacks and Hispanics had the lowest rates of statin use among these three risk groups. Only 24.7% of the women with an ASCVD score of ≥ 7.5% were on a statin. Blacks were more likely to have an ASCVD risk score ≥ 7.5% than Whites (OR=5.6, confidence interval [CI] 3.5-8.8). Of statin eligible women, 18.8% of the Black women were on a statin compared to 36.4% of the White women. Though not statistically significant, Blacks were less likely to be on a statin (OR=0.57, 95% CI 0.21-1.39) compared to Whites. 
Conclusion: 
Among a large, multiethnic cohort of midlife women, women in the four groups recommended for statin therapy by the current AHA guidelines, have low rates of statin use. Rates of statin use were low across all race/ethnic groups. Minority women, in particular, Blacks were more likely to fall into one of the four groups recommended for statin use. 
Public health significance:
One out of every six deaths in the United States is due to coronary heart disease. Eating habits and other lifestyle factors play a key role in causing heart disease. The approach for primary prevention of cardiovascular events depends on assessing the risk using various scores. Our results indicate that risk assessment using the 2013 ACC/AHA guidelines for estimating 10-year atherosclerotic cardiovascular disease risk, could lead to lower rates of cardiovascular events. Accurate identification of such people allows healthcare professionals, policymakers and others to target prevention and treatment to those at the highest risk of morbidity and mortality.
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	Globally, the incidences of cardiovascular diseases are increasing at an alarming rate. Nearly 2,200 Americans die of cardiovascular diseases daily, with an average of one death occurring every 40 seconds. Studies show that hyperlipidemia is an important risk factor for cardiovascular diseases. ADDIN EN.CITE (). LDL-C, total cholesterol and triglycerides are directly related to cardiovascular disease prevalence (). Therefore, primary prevention of cardiovascular events includes lipid management. Individuals’ ≥21 years of age with LDL-C (≥190 mg/dL) are placed in the highly susceptible category for developing atherosclerotic cardiovascular events during their lifetime due to genetic predisposition. For every 39 mg/dL decrease of LDL-C level using statins, the risk for cardiovascular diseases lowers by 20%.  (). A Clinical trial using Atorvastatin reported that, 10 mg daily, is safe and effective for the primary prevention of major cardiovascular events in patients with type 2 Diabetes Mellitus (DM) with LDL-C of 4.14mmol/L (74.6 mg/dL)  ADDIN EN.CITE (). However, no justification is available for specifying a particular threshold level of LDL-C as the sole arbiter at which patients with type 2 diabetes should receive statins. Other studies have suggested that 6 - 12 months of treatment with statins elicits beneficial cardiovascular effects  ADDIN EN.CITE ().  
Estimating cardiovascular risk in an asymptomatic population is a challenge.  Therefore, developing efficient methods for calculating the risk for future cardiovascular events is of paramount importance. The widely used risk assessment method until 2013 was the Framingham Risk Score (FRS) method which estimated 10 - year coronary risk. However, the FRS underestimates risk in women because for a given risk score, the 10-year risk for a woman is lower than that for a man. Consider, for example, a 55-year-old man who has a total cholesterol level of 250 mg/dL and an HDL-C level of 40 mg/dL, is a nonsmoker, has a systolic blood pressure (SBP) measurement of 160 mm Hg, and is on no medications. Using the ATP III tables, his point count is 15 equivalent to a 10-year cardiovascular risk of 20%, elevating him to a cardiovascular risk equivalent (e.g., stroke, aortic aneurysm, peripheral arterial disease, DM, metabolic syndrome). In contrast, a woman with exactly the same numbers would receive a higher point count of 18, but her 10-year cardiovascular risk would only be 6%. Although the difference is because men are at risk 10 years earlier than women, this feature of the FRS tool has received criticism. () 
1.1	Cardiovascular risk assessment
	Two cardiovascular risk assessment algorithms, namely 2013 ACC/AHA 10-year ASCVD and FRS, were used to calculate the 10-year risk of a cardiovascular event in this study. These scores were then used to identify statin eligible women in the study sample.
1.1.1	Framingham risk Score (FRS)
The FRS is a risk prediction model that has been used in the general population to forecast cardiovascular events and to tailor preventative therapy from 2008 to 2013. The FRS calculates the 10-year risk for coronary events using a combination of risk factors: chronological age, gender, total cholesterol, HDL-C, smoking history, systolic blood pressure (SBP), and presence of DM. However, other risk factors such as metabolic syndrome (abdominal obesity, atherogenic dyslipidemia, insulin resistance ± glucose intolerance, proinflammatory state, prothrombotic state) and family history are not included in the calculation. 
	The FRS categorizes coronary risk as low risk (0-10%), intermediate risk (10-20%) or high risk (20% and higher) for coronary events within 10 years. Additionally, intermediate risk is subdivided into moderate risk or moderately high risk. Moderate risk includes those with a low risk FRS and 2 or more risk factors.  Moderately high risk involves those with intermediate FRS risk and 2 or more risk factors. The risk factors for this sub-classification are cigarette smoking, hypertension (HTN) (140/90 mmHg or on therapy), low HDL-C (<40 mg/dL), family history of early heart disease (father or brother <55 years old, mother or sister <65 years old) and age (45 or older males, 55 or older females). Based on the risk categories , pharmacological and/or non-pharmacological interventions are recommended as per the National Cholesterol Education program ATPIII guidelines ()
1.1.2	2013 ACC/AHA 10-year ASCVD score
	The 2013 ACC/AHA 10-year ASCVD estimates 10-year risks for atherosclerotic cardiovascular disease. The information required to estimate the ASCVD risk includes age, sex, race, total cholesterol, HDL-C, SBP, blood pressure lowering medication use, presence of DM, and smoking status. Compared with the FRS, the ASCVD additionally includes race and use of blood pressure lowering medication. (). According to these guidelines, statin therapy were recommended for women with vascular diseases (CAD, CVD), presence of DM (between the ages of 40 and 74), LDL-C ≥ 190 mg/dl and  an ASCVD score ≥ 7.5%.
	In 2013 the ACC/AHA offered this  new risk estimation algorithm to guide cardiovascular disease prevention strategies  ADDIN EN.CITE () (). However, the performance of this new algorithm for cardiovascular risk estimation in midlife women across different ethnicities has not been assessed. In this study we primarily aimed to compare the ASCVD scale with the FRS algorithm to detect statin eligibility. The impact of the changes in guidelines is likely to increase the numbers of women who are eligible for statin therapy. In addition, it is likely that statin usage differs significantly by race/ethnicity. Currently little is known about the eligibility and prescribing patterns of statins among women, particularly in different racial or ethnic groups.
1.1.3	Hypotheses
	Using the most recent data (Visit 12), we propose the following hypotheses. 
1.	Under the new guidelines more women will be statin eligible compared to prior guidelines. Black and Hispanic women will have the greatest difference in statin eligibility between the old and new guidelines. Blacks and Hispanics, who are statin eligible, will be   less likely to be taking statins. 
2.	Among women who are eligible for statins (according to the 2013 Lipid Guidelines and  ATP III definitions), lower rates of statin use will be observed among Black women compared with  other racial and ethnic groups. 
2.0 	METHODS
	The Study of Women’s Health across the Nation (SWAN) is a multi-site longitudinal, epidemiologic study designed to examine the health of women during their middle years. The study examines the physical, biological, psychological and social changes occurring during this transitional period. The goal of SWAN’s research is to help scientists, health care providers and women learn how mid-life experiences affect health and the quality of life during aging. The research centers are located in: Ann Arbor, MI (University of Michigan), Boston, MA (Massachusetts General Hospital), Chicago, IL (Rush University Medical Center), Alameda and Contra Costa County, CA (University of California Davis and Kaiser Permanente), Los Angeles, CA (University of California at Los Angeles), Jersey City, NJ (Albert Einstein College of Medicine), and Pittsburgh, PA (University of Pittsburgh). SWAN participants represent five racial/ethnic groups namely Whites, Blacks, Hispanics, Chinese and Japanese and a variety of backgrounds and cultures between the ages of 40-70 years. 
	The primary outcome of interest is statin use. The independent variables assessed included age, race, smoking status, presence of DM, presence of CAD (myocardial infarction, angina, revascularization including coronary artery bypass grafting (CABG) and/or PCI (percutaneous coronary intervention), stroke/Transient ischemic attack (TIA), and carotid disease). HTN is defined as a SBP ≥140 mmHg or a DBP ≥ 90 mmHg or using antihypertensive medications.  Family history of premature coronary artery disease is defined as coronary artery disease in a first degree relative: male age ≤55, female age ≤65. Other SWAN covariates included total cholesterol, LDL-C, HDL-C, triglycerides, hormone use (current, past, never), final menstrual period, C-reactive protein, waist circumference, income, study site and body mass index (BMI).
2.1.1	Sample for analysis
	From 3302 women at SWAN baseline, the study population was composed of those who contributed data at Visit 12 (2009- 2011) (N=2399). We examined all Visit 12 women in the SWAN cohort and calculated the FRS and ASCVD risk scores for those who had all components of the scores available. After exclusion of patients with CAD, CVD, DM, prior history of statin use (women who were already on statins (244/1904) would have a modified total cholesterol) or those with missing data on components of the ASCVD score  at baseline,  1315  women were available for estimating risk using the scores (Fig 1). 
In order to test the rate of statin use across various ethnicities, women were grouped into the four groups defined by the 2013 ACC/AHA lipid guidelines. These groups were:
1.	Women with CAD or CVD, but without DM
2.	Women who had one or more lipid profiles with LDL-C ≥ 190mg/dL but without  CAD, CVD or DM
3.	Women with DM and  LDL-C  ˂  190mg/dL, but without CAD or CVD 
























Figure 1. Flow chart for analysis sample

Women were also grouped according to ATP III definitions using the FRS.  These groups included:
1.	High risk: Women with CAD or CVD or FRS  ≥  20%
2.	Medium high risk: Women with 2 or more risk factors (smoking, DM, HTN and family history of premature CAD) and FRS of 10-20% with an LDL-C ≥ of 130mg/dL
3.	Moderate risk: Women with 2 or more risk factors and a FRS of < 10% and  an LDL-C ≥ 160mg/dL 
4.	Low risk: Women with 0-1 risk factor but with an LDL-C ≥190mg/dL.
2.1.2	Statistical analysis
	Baseline characteristics of the Visit 12 women were compared using measures of central tendency (mean, SD, percent, frequency) and analyzed using the appropriate test (Analysis of Variance (AOV), Chi-square). P-values were calculated using Chi-square test (exact test if appropriate) and AOV or Kruskal Wallis tests for continuous variables depending on the normality of the data. 











Table 1. Demographics of women at Visit 12 after excluding those with CAD, CVD, DM or both
 	Total	Black	Caucasian	Chinese	Hispanic	Japanese	
 	N=1315	N=316	N=663	N=135	N=58	N=143	
Variable	n (col %)	n (col %)	n (col %)	n (col %)	n (col %)	n (col %)	P-value
Age, mean (SD)	60.1 (2.7)	59.6 (2.6)	60.2 (2.7)	60.4 (2.5)	60.1 (2.8)	60.8 (2.7)	<.0001
BMI, mean (SD)	28.3 (7)	32.3 (7.4)	28.2 (6.5)	23.2 (3.4)	30.7 (6.2)	23.7 (4.6)	<.0001
Waist circumference, mean (SD)	88.2 (15.3)	96.2 (14.9)	88.2 (14.7)	79.3 (10.5)	93.6 (13.5)	76.9 (11.3)	<.0001
Waist hip ratio, mean  (SD)   	0.8 (0.07)	0.8 (0.07)	0.8 (0.07)	0.8 (0.06)	0.8 (0.07)	0.8 (0.06)	<.0001
SBP  (mmHg), mean (SD)	120.9 (17.2)	129.3 (17.2)	118.1 (15.5)	111.9(12.9)	129.1 (20.1)	118.6 (17.5)	<.0001
DBP  (mmHg), mean (SD)	74.6 (10.5)	79.3 (10.6)	73.5 (9.7)	68.3 (8.2)	77.2 (10.9)	74 (11)	<.0001
Total cholesterol (mg/dl),mean (SD)	212.8 (36.2)	204.7 (38.2)	214.8 (36)	212.6 (37.1)	210.5 (32.3)	222.7 (29.4)	<.0001
HDL-C (mg/dl), mean                    (SD)	65.1 (16.5)	61.2 (16.5)	65.9 (16.6)	68.1 (15.8)	58.4 (12.6)	69.9 (16.1)	<.0001
LDL-C (mg/dl), mean (SD)	125.8 (30.8)	124.5 (33)	126.8 (30.2)	121.4 (31.4)	126.3 (28.2)	127.9 (29)	<.0001
Triglycerides (mg/dl), mean(SD)	109.3 (54.8)	96 (41.7)	108.2 (51.3)	115.6 (57)	128.8 (55.9)	129.9 (79.4)	<.0001
# yrs. since clean/imputed FMP	7.9 (3.3)	7.7 (3.3)	7.8 (3.2)	8.5 (3.3)	8.5 (4)	8 (3.5)	<.0001
Risk Scores							
ASCVD score (%), mean (SD)	4.4(3.6)	7.2 (5.2)	3.5 (2.1)	2.8 (1.4)	4.9(3)	3 (2.3)	<0.001
Framingham Score (%), mean (SD)	12.8 (2.5)	14 (2.8)	12.6 (2.2)	11.7 (1.9)	14.2 (2.7)	12.6 (2.1)	<0.001
Framingham Score category, N (%)							0.0099
>20%	1 (0.08)	1 (0.3)	0	0	0	0	
11-17%	11 (0.8)	7 (2.2)	1 (0.2)	0	2 (3.5)	1 (0.7)	
0-8%	1303 (99.1)	308 (97.5)	662 (99.9)	135 (100)	56 (96.6)	142 (99.3)	
Hormone users, N (%)							<.0001
Current 	67 (5.1)	11 (3.5)	46 (6.9)	5 (3.7)	0	5 (3.5)	
Past 	421 (32)	91 (28.8)	250 (37.7)	29 (21.5)	8 (13.8)	43 (30.1)	
Never 	827 (62.9)	214 (67.7)	367 (55.4)	101 (74.8)	50 (86.2)	95 (66.4)	
Site, N (%)							<.0001
Michigan	192 (14.6)	120 (38)	72 (10.9)	0	0	0	
MGH	214 (16.3)	78 (24.7)	136 (20.5)	0	0	0	
UC Davis	140 (10.7)	63 (19.9)	77 (11.6)	0	0	0	
UCLA	245 (18.6)	0	110 (16.6)	135 (100)	0	0	
Pittsburgh	247 (18.8)	0	104 (15.7)	0	0	143 (100)	
Chicago	92 (7)	0	34 (5.1)	0	58 (100)	0	
New Jersey	185 (14.1)	55 (17.4)	130 (19.6)	0	0	0	
Antilipemic drugs, N (%)							
Statin	42 (3.2)	21 (6.7)	16 (2.4)	0	2 (3.5)	3 (2.1)	0.0011
 Fibrate	7 (0.5)	1 (0.3)	6 (0.9)	0	0	0	0.7049
Other	10 (0.8)	2 (0.6)	6 (0.9)	1 (0.7)	0	1 (0.7)	1
Comorbidities, N (%)							
Hypertension**	501 (38.1)	201 (63.6)	201 (30.3)	27 (20)	30 (51.7)	42 (29.3)	<.0001
Family history of CAD, N (%)***	763 (60.5)	176 (60.3)	418 (64.7)	66 (49.6)	26 (52)	77 (55)	0.0055
Income, N (%)****							<.0001
Less than $20,000	92 (7.6)	37 (12.9)	23 (3.7)	8 (6.6)	20 (36.4)	4 (3.2)	
$20,000-49,999	139 (11.4)	65 (22.7)	50 (7.9)	7 (5.8)	8 (14.6)	9 (7.2)	
$ 50,000-99,999	169 (13.9)	57 (19.9)	74 (11.7)	13 (10.7)	9 (16.4)	16 (12.8)	
$ 100,000-149,999	260 (21.3)	62 (21.6)	133 (21.1)	27 (22.3)	9 (16.4)	29 (23.2)	
$150,000 or more	559 (45.9)	66 (23)	351 (55.6)	66 (54.6)	9 (16.4)	67 (53.6)	
* 9 missing values
** Hypertension definition: SBP≥140 mmHg or DBP≥ 90 mmHG or use of antihypertensive medications.
***Family history of CAD definition: CAD in first degree relative male≤55 years or female ≤65 years. (54 missing values)
****96 missing values




3.1.2	Statin eligibility and use
The eligibility for statin use based on ASCVD and FRS are given in Table 2. 174 (13.2%) of women were statin eligible by ASCVD score, 12 (0.9%) by FRS score, 12 (0.9%) by both scores and 1141 (86.8%) not eligible by either score. The 12 statin eligible women identified by the FRS were also ascertained by the ASCVD score. The FRS did not recognize any woman not distinguished by the  ASCVD score Clearly, the FRS approach substantially reduced the proportion of subjects eligible for statin therapy compared with the ASCVD score (13.2% vs. 0.9%; P-value < 0.0001). The ASCVD score determined that 32.9% of the Blacks, 6.5% of the Whites, 1.5% of the Chinese, 12.1% of the Hispanics and 4.2% of the Japanese were statin eligible. After adjusting for site, age, BMI, and education, the odds of having an ASCVD risk score ≥ 7.5% is 5.6 times higher in Blacks compared to Whites (OR=5.6, confidence interval [CI] 3.5-8.8).




Table 2. The eligibility for statin use based on ASCVD score (≥ 7.5%) and Framingham risk Score (FRS) (≥ 10%)
 	Total	Black	Caucasian	Chinese	Hispanic	Japanese	
 	N=1315	N=316	N=663	N=135	N=58	N=143	
Variable	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)	P-value
Eligibility based on risk scores							<.0001
Only ASCVD score	162 (12.32)	104 (32.9)	43 (6.5)	2 (1.5)	7 (12.1)	6 (4.2)	
Only Framingham score	0	0	0	0	0	0	
Both scores	12 (0.9)	8 (2.5)	1 (0.2)	0	2 (3.5)	1 (0.7)	
Not eligible per either scores	1141 (86.8)	204 (64.6)	619 (93.4)	133 (98.5)	49 (84.5)	136 (95.1)	
*P-values are calculated using chi-Square (exact tests if appropriate).

Table 3. Statin use among women who are eligible under ASCVD score and FRS
 	Total	Black	Caucasian	Chinese	Hispanic	Japanese	 
 	N=1315	N=316	N=663	N=135	N=58	N=143	 
 	n (col%)	n (col%)	n (col%)	n (col%)	n (col%)	n (col%)	P-value
Eligible by only ASCVD scores(n=162)							0.1161
statin users	40 (24.7)	20 (19.2)	15 (34.9)	0	2 (28.6)	3 (50)	 
Non-statin users	122 (75.3)	84 (80.8)	28 (65.1)	2 (100)	5 (71.4)	3 (50)	 
Eligible by both scores (n=12)	 	 	 	 	 	 	0.3333
statin users	2 (16.7)	1 (12.5)	1 (100)	0	0	0	 
Non-statin users	10 (83.3)	7 (87.5)	0	0	2 (100)	1 (100)	 
Not eligible by either scores (n=1141)	 	 	 	 	 	 	 
Non-statin users	1141 (100)	204 (100)	619 (100)	133 (100)	49 (100)	136 (100)	 
*P-values are calculated using chi-Square (exact tests if appropriate)

The subgroups based on 2013 ACC/AHA guidelines (ASCVD) and ATP III guidelines (FRS) and statin usage in each group are shown in Table 4 and Table 5 respectively. When comparing statin use, it was found that among women with CAD or CVD diagnosis, 36.2% of Blacks, 42.9% of Whites and 12.5% of Hispanics used statins (P-value=0.5). Among women with LDL-C ≥190 mg/dL, 13.3% of Blacks, 9.1% of Whites and 50% of Hispanics were on statins (P-value=0.42). Among women with DM, 50% of Blacks, 62.5% of Whites and 62.5% of Hispanics were on statins (P-value=0.12). Of women who had an ASCVD score ≥7.5%, but no diagnosis of CAD, CVD or diabetes, 19.2% of the Blacks and 28.6% of the Hispanics were on a statin compared to 34.9% of Whites. (P-value=0.12).








Table 4. Statin use based on 2013 ACC/AHA guidelines (ASCVD)
1. Women with vascular disease(CAD/CVD)                                                                                                                  P-value                                                                                         
Total (N=141)	Black (N=58)  	Caucasian (N=63)	Chinese (N=8)	Hispanic (N=8)	Japanese (N=4)	 0.4858
52 (36.9)	21 (36.2)	27 (42.9)	2 (25)	1 (12.5)	1 (25)	
2. Women with LDL-C ≥ 190mg/dL, but without CAD, CVD or diabetes
Total (N=47)	Black (N=15)  	Caucasian (N=22)	Chinese (N=5)	Hispanic (N=2)	Japanese (N=3)	 0.4203
6 (12.8)	2 (13.3)	2 (9.1)	1 (20)	1 (50)	0	
3.Women with Diabetes  and LDL-C ˂190 mg/dL , but without CAD or CVD 
Total (N=260)	Black (N=105)  	Caucasian (N=96)	Chinese (N=15)	Hispanic (N=24)	Japanese (N=20)	 0.1189
154 (59.2)	53 (50.5)	60 (62.5)	12 (80)	15 (62.5)	14 (70)	
4.Women with ASCVD score ≥ 7.5% , but without CVD, CAD or diabetes but 
Total (N=162)	Black (N=104)  	Caucasian (N=43)	Chinese (N=2)	Hispanic (N=7)	Japanese (N=6)	 0.1161
40 (24.7)	20 (19.2)	15 (34.9)	0	2 (28.6)	3 (50)	






Table 5. Statin use based on ATP III guidelines (FRS)
1. HIGH RISK: Women with vascular disease(CAD/CVD) or FRS ≥ 20%	P-value
Total (N=235)	Black (N=112)	Caucasian (N=90)	Chinese (N=11)	Hispanic (N=17)	Japanese (N=5)	0.4142
116 (49.4)	60 (53.6)	44 (48.9)	5 (45.5)	6 (35.3)	1 (20)	
2. MODERATE HIGH RISK: Women with 2 or more risk factors and FRS between 10-20% with an LDL-C ≥ 130mg/dL	 
Total (N=13)	Black (N=9)	Caucasian (N=1)	Chinese (N=0)	Hispanic (N=2)	Japanese (N=1)	 0.4545
3 (23.1)	2 (22.2)	1 (100)	0	0	0	
3.MODERATE RISK: Women with 2 or more risk factors and FRS ≤10 % with  LDL-C ≥ 160mg/dL	 
Total (N=55)	Black (N=23)	Caucasian (N=21)	Chinese (N=2)	Hispanic (N=5)	Japanese (N=4)	 0.6555
8 (14.6)	5 (21.7)	2 (9.5)	0	1 (20)	0	
4.LOW RISK: Women with 0-1 risk factor but with LDL-C ≥ 190mg/dL	 
Total (N=35)	Black (N=8)	Caucasian (N=19)	Chinese (N=5)	Hispanic (N=0)	Japanese (N=3)	 0.7015
5 (14.3)	2 (25)	2 (10.5)	1 (20)	0	0	





This study examined racial differences in statin eligibility and use in SWAN women. It was hypothesized that under the 2013 ACC/AHA guidelines based on ASCVD score, more women would be statin eligible. It was also hypothesized that compared to White women, Black and Hispanic women would have the greatest difference in statin eligibility and use.. 
While evaluating the overall demographics of the study sample, Blacks had the highest mean ASCVD score, followed by Hispanics. The mean FRS were higher in both Blacks and Hispanics compared to other races.
Upon analysis of the sample (n=1315) for their risk using the scores, more women were found to be statin eligible based on the ASCVD scores vs FRS. There were none eligible ‘only’ by FRS and all those eligible by FRS were also eligible by ASCVD score. This is attributed to the overlap of parameters involved in the calculation of both scores. The FRS and ASCVD are calculated using the same parameters except that the ASCVD additionally includes race and use of blood pressure lowering medication. Among those eligible by ASCVD scores, Blacks and Hispanics had the lowest rate of statin use, but was statistically not significant, possibly due to the small sample size. 
There are different approaches for calculating the risk for cardiovascular diseases apart from the risk calculation based on the 2013 ACC/AHA guidelines.  Recently, a so-called “trial based” approach has been proposed in which statins will be offered to patient populations for whom RCTs support statin efficacy, disregarding individual risk assessment and absolute risk. A hybrid approach which includes both trial based and risk calculation based on the 2013 ACC/AHA guidelines is also being studied. The primary prevention for atherosclerotic cardiovascular disease with statins based on risk assessment is highly recommended. A study that compared a trial-based and hybrid approaches for statin treatment eligibility in Copenhagen General Population Study (CGPS) showed that clinical performance of the 2013 ACC/AHA guidelines based approach for primary prevention of cardiovascular disease with statins was superior to the trial-based and hybrid approaches (). Our results indicate that risk assessment using the ACC/AHA guidelines for estimating 10-year atherosclerotic cardiovascular disease risk (ASCVD), could  lead to lower rates of cardiovascular events, through early identification of risk and initiation of pharmacological and non-pharmacological interventions. 
	The ACC/AHA guidelines recommend the new 7.5% risk threshold based on risk/benefit considerations (). As age dominates the risk predictors, the scores rise as age increases, which will favor statin treatment in older people, disregarding younger people with a high lifetime ASCVD risk. However, the ACC/AHA guidelines recommend statin therapy initiation only after a clinician–patient discussion in order to determine benefits, harms, and patient preferences, allowing for more lenient initiation of preventive measures in older subjects with favorable risk factors.
	In CGPS, a larger proportion of participants, would qualify for statin therapy with the trial-based approach compared to the ACC/AHA risk-based approach, meaning that statin treatment should be initiated at a much earlier age in women at low risk (). This finding may be surprising and creates concern about potential overuse of statins based on the new ACC/AHA guidelines. The concerns related to statin overuse are muscle pain, muscle damage, liver damage, digestive issues, rash, flushing, increased blood sugar and neurological side effects.          
	Our study has some limitations. One of which is that we used Visit 12 data (2009-2011). All the reported statin use data were based on the guidelines prior to 2013.  As SWAN includes only midlife women, the study results lack generalizability to men and younger populations, age ≤ 45 years. 38% of our study population had HTN. There are possibilities for the overestimation of cardiovascular risk using ASCVD scores in this group, as the use of blood pressure lowering medications is included in the risk calculation. This concern does not apply to the FRS approach.  The study sample size was possibly too small to obtain a statistically significant result. We included only those women who were statin eligible as per ASCVD score. The sample size for the various subgroups analysis as per ATP III guidelines and 2013 ACC/AHA algorithm were very small. Future study of a large sample may lead to statistically significant results. Moreover, the algorithm used to calculate the risk scores was validated only in Non-Hispanic Whites with a mean age of 49 years (range 30-74) ().  There were no separate cutoffs for Blacks, Hispanics and Asians and the results may change if they are excluded from the study. 
	Our study also possesses a number of strengths. Our results originate from a contemporary, population-based, large cohort with extensive follow-up data. In addition, predicted outcomes were appropriately identified and adjudicated. The study results were generalizable to 5 races and a midlife female population.
	The future direction of the study will be to test both the scores on the most recent Visit 13 data. Assessment of larger and independent populations is also necessary to confirm our initial observations. Also, more studies are needed to assess the reasons for racial disparities in statin eligibility and use. Insurance status could be one of the most important reasons behind underuse of statins in minority population. According to the reports from the CDC (2011-2012) statin use was three times greater among adults aged 40–64 with health insurance (23.9%) than among those without health insurance (8.1%). Among adults aged 40–64 with a prescription drug benefit, 24.3% used statins compared with 9.3% of those who did not have a prescription drug benefit(). Concerns over adverse drug events may also be an issue. A number of manifestations of muscle degeneration have been reported with statin use, with rhabdomyolysis the most feared.  Physician awareness of such events is reportedly low even for those events most widely reported by patients  ADDIN EN.CITE (). 

5.0 	Conclusion
	The practice of preventive cardiology necessitates the identification of high-risk patients who are most likely to have cardiovascular events. No individual risk factor is a good predictor of cardiovascular events, but a combination of information provides an accurate tool for risk evaluation. The best approach to risk assessment in patients seen most frequently in internal medicine practices is to use risk assessment calculation tools. In our study, we compared the efficiency of two such tools, namely FRS and ASCVD scores in predicting the statin eligibility of SWAN women.
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3302 women at SWAN (Baseline)



















Missing components in risk sores (n=345)

Not eligible by either scores; but statin users (n=244)

1315 women included in the analysis sample

162 eligible only ASCVD score

1141not eligible by either score

12 eligible by both scores

0 eligible by only Framingham score

0 statin users

122 non-statin users

0 statin users

0 non-statin users

11411 non-statin users

10 non-statin users

2 statin users

Table 1 Continued
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